





(a)



(b)

Figure4 43 relapsed/primary refractory DLBCL patients treated with rituximab-salvage therapy identified by the saalPI as intermediate risk (saalPI=1-2) were further stratified into $ALC/AMC \geq 2.0$ or $ALC/AMC < 2.0$ groups by the ALC/AMC ratio (a,b). (Kaplan-Meier estimates of overall survival and progression-free survival are shown)